Evidence map›Paper›PMID 40673086›Full record

ArticleTranslational lung cancer research2025

Utility of CK8/18 in identifying circulating tumor cells derived from lesions in patients with non-small cell lung cancer.

Tetsuya Sakai, Mami Onishi, Yoshitaka Zenke, Eri Morita Yamamoto, Yuichi Ijiri, Kana Kawasaki, Fumie Kato, Tomoko Sugano, Bishnu Devi Maharjan, Ali Asgar S Bhagat and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tetsuya Sakai *Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.
Mami Onishi *Sysmex Corporation, Kobe, Japan.
Yoshitaka ZenkeDepartment of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.
Eri Morita YamamotoSysmex Corporation, Kobe, Japan.
Yuichi IjiriSysmex Corporation, Kobe, Japan.
Kana KawasakiSysmex Corporation, Kobe, Japan.
Fumie KatoSysmex Corporation, Kobe, Japan.
Tomoko SuganoSysmex Corporation, Kobe, Japan.
Bishnu Devi MaharjanSysmex Corporation, Kobe, Japan.
Ali Asgar S BhagatBiolidics Limited, Singapore, Singapore.
Tomokazu YoshidaSysmex Corporation, Kobe, Japan.
Shigeki IwanagaSysmex Corporation, Kobe, Japan.
Masatoshi YanagidaSysmex Corporation, Kobe, Japan.
Koichi GotoDepartment of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Circulating tumor cells (CTCs) are identified by the absence of pan-leukocyte markers and positive staining for cytokeratin (CK). Anti-panCK antibody (AE1/AE3) is a widely used marker for CK. However, epithelial-mesenchymal transition reduces the expression of panCK markers, leading to low detection rates of CTCs, especially in non-small cell lung cancer (NSCLC). This study aimed to evaluate the efficacy of a novel CTC detection system using CK8/18 as an epithelial cell marker in patients with NSCLC. Methods: A total of 20 patients with NSCLC (10 Results: CTCs were detected in 17 patients (8 Conclusions: This study demonstrated the effectiveness of CK8/18 over panCK in detecting CTCs. Adopting CK8/18 in the novel system improved the detection rate of CTCs, highlighting its potential in clinical applications.

Indexed as

Circulating tumor cells (CTCs)cytokeratin 8/18 (CK8/18)imaging flow cytometerlung cancersingle cell gene mutation

Identifiers

PMID40673086
PMCPMC12261347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.